Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab + TCS in Children with Severe Atopic Dermatitis
NCT03345914Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2017
- Primary completion
- Jun 2019
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 3 trial of dupilumab in atopic dermatitis (AD), sponsored by Regeneron Pharmaceuticals. Started Nov 2017; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03345914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03345914.